NCT06597058 is a double-blind, placebo-controlled Phase 2 estimation study evaluating the efficacy and safety of a fixed-dose combination polypill (MAR Active 0.6g tablet) in subjects with Alzheimer's Disease. Sponsored by Noah Pharmaceuticals, Inc., the trial enrolled 103 participants and is designed to estimate treatment effect across multiple cognitive and functional endpoints[1].
The MAR polypill represents a multi-target, combination therapy approach to Alzheimer's disease — combining multiple pharmacological agents in a single tablet to address the multifactorial pathophysiology of AD. This strategy differs from single-target monoclonal antibody approaches (like lecanemab or donanemab) by targeting multiple disease pathways simultaneously through synergistic drug combinations[2].
The polypill approach is grounded in the understanding that Alzheimer's disease involves multiple interconnected pathophysiological mechanisms — including amyloid accumulation, tau pathology, neurotransmitter deficits, neuroinflammation, and metabolic dysfunction — and that addressing these simultaneously may produce greater clinical benefit than targeting a single pathway[3].
| Field | Value |
|---|---|
| NCT Number | NCT06597058 |
| Title | A Double-Blind, Placebo-Controlled Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill Administered to Subjects With Alzheimer's Disease |
| Phase | Phase 2 |
| Status | Recruiting / Active |
| Sponsor | Noah Pharmaceuticals, Inc. |
| Intervention | MAR Active 0.6g tablet (experimental) vs MAR Placebo 0.6g tablet |
| Participants | 103 (estimated) |
| Age Range | 50-85 years |
| Condition | Alzheimer's Disease (very mild to severe) |
| Study Design | Randomized, triple-blind (participant, care provider, investigator), placebo-controlled, parallel-group |
| Start Date | October 16, 2024 |
| Primary Completion | December 31, 2025 (estimated) |
| Study Completion | February 15, 2026 (estimated) |
The polypill strategy — combining multiple approved drugs in a single formulation — originated in cardiovascular medicine, where fixed-dose combination pills have demonstrated significant improvements in adherence and outcomes for hypertension, dyslipidemia, and secondary prevention[4]. The translation of this approach to Alzheimer's disease reflects growing recognition that AD is a multifactorial disease requiring multi-target intervention[5].
Pathway Complexity: AD involves simultaneous dysfunction across amyloid processing, tau phosphorylation, cholinergic transmission, glutamate excitotoxicity, neuroinflammation, oxidative stress, and metabolic deficits — no single drug can address all these targets effectively.
Synergistic Effects: Fixed-dose combinations allow multiple agents to work synergistically, potentially amplifying therapeutic benefit while maintaining tolerability.
Improved Adherence: A single pill simplifies the medication regimen for patients with cognitive impairment, reducing the burden on caregivers and improving compliance with multi-drug regimens.
Repurposing Advantage: The polypill can combine established generic medications with proven safety profiles, potentially reducing development timelines and costs compared to novel single-target agents.
Individualized Components: While delivered as a single pill, each component targets a distinct pathway — enabling a broader therapeutic reach than any single agent.
| Approach | Examples | Mechanism | Advantages | Limitations |
|---|---|---|---|---|
| Anti-amyloid mAbs | Lecanemab, Donanemab | Remove amyloid plaques | Disease-modifying, biomarker evidence | ARIA risk, IV administration, cost |
| Cholinesterase inhibitors | Donepezil, Rivastigmine | Boost acetylcholine | Oral, well-established | Symptomatic only |
| Polypill/Multi-target | MAR (NCT06597058) | Multiple pathways | Synergistic, oral, repurposed agents | Unproven in AD, complexity |
| Symptomatic agents | Memantine, Exelon | Various | Symptomatic benefit | Do not modify disease |
Noah Pharmaceuticals, Inc. is a pharmaceutical company focused on the development of combination therapies for neurological disorders[6]. The MAR polypill represents their approach to Alzheimer's disease through multi-target combination therapy, leveraging the synergistic potential of multiple established agents.
The company's focus on fixed-dose combinations aligns with broader trends in CNS drug development emphasizing polypharmacology and pathway crosstalk[7].
This is a Phase 2 estimation study — designed to estimate the magnitude of treatment effect across multiple endpoints, not to definitively establish efficacy. Phase 2 estimation studies typically inform Phase 3 sample size calculations and confirmatory trial design.
The triple-blind design (participant, care provider, and investigator blinded) represents a particularly rigorous blinding approach, minimizing bias in both subjective endpoint assessments and objective measures.
Randomization (1:1)
|
+---> MAR Active 0.6g tablet (QD or as directed)
| |
| v
| Double-blind treatment period
| |
+---> MAR Placebo 0.6g tablet
|
v
Placebo-controlled observation
Based on the trial design and endpoints, expected inclusion criteria include:
The trial uses a multi-domain endpoint approach assessing cognitive, functional, and global measures[1:1]:
| Endpoint | Instrument | Description |
|---|---|---|
| CDR-GS | Clinical Dementia Rating — Global Score | Global dementia severity |
| CDR-SB | Clinical Dementia Rating — Sum of Boxes | Sum of 6 domain scores (0-18 scale) |
| MMSE-2 | Mini-Mental State Examination 2nd Edition | Global cognitive function (0-30) |
| ADAS-COG | Alzheimer's Disease Assessment Scale — Cognitive Subscale | Standardized cognitive assessment |
| ADCS-ADL | Alzheimer's Disease Cooperative Study — ADL | Daily living activities |
| CGI-I | Clinical Global Impressions — Improvement | Investigator-rated global improvement |
| CGI-S | Clinical Global Impressions — Severity | Investigator-rated global severity |
| Endpoint | Monitoring |
|---|---|
| TEAEs | Treatment-emergent adverse events |
| SAEs | Serious adverse events |
| AEs | General adverse event monitoring |
The CDR is a standardized instrument assessing six domains of cognitive and functional performance:
The CDR-GS provides an overall staging score (0 = normal, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe), while the CDR-SB provides a continuous measure sensitive to change in early stages.
The Mini-Mental State Examination, Second Edition is a brief 30-point screening test assessing:
A score range of 8-24 reflects moderate to severe cognitive impairment.
The ADAS-COG is the gold-standard cognitive outcome measure in AD clinical trials, assessing:
Higher scores indicate greater impairment.
The ADCS-ADL assesses functional abilities through caregiver/informant report, covering:
The MAR polypill is formulated as a 0.6g tablet containing multiple active pharmaceutical ingredients in a fixed-dose combination. The specific drug combination is proprietary, but polypill strategies for Alzheimer's disease typically include agents targeting:
The combination of multiple agents in a single pill enables:
Alzheimer's Disease is the most common cause of dementia, affecting an estimated 6.7 million Americans aged 65 and older[8]. The disease is characterized by:
The current AD treatment landscape includes:
Symptomatic therapies:
Disease-modifying therapies:
Combination therapy rationale:
The rationale for multi-target approaches like the MAR polypill is strong given the modest efficacy of single-target agents and the complex, multifactorial nature of AD pathophysiology[9].
Positive signals:
Challenges:
If the MAR polypill demonstrates efficacy:
A Double-Blind, Placebo-Controlled Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill Administered to Subjects With Alzheimer's Disease. ↩︎ ↩︎
The polypill concept: a platform for cardiovascular disease and neurodegeneration prevention. Nature Reviews Cardiology. 2023. ↩︎
The AD polypill: progress and perspectives in Alzheimer's disease prevention. Alzheimer's & Dementia. 2022. ↩︎
Cardiovascular polypill for secondary prevention. The Lancet. 2023. ↩︎
Multifactorial nature of Alzheimer's disease pathophysiology. Nature Neuroscience. 2023. ↩︎
Fixed-dose combination drugs in CNS disorders. Expert Opinion on Pharmacotherapy. 2023. ↩︎
Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2024. ↩︎
Combination therapy approaches for Alzheimer's disease. Lancet Neurology. 2022. ↩︎